ClinicalTrials.gg
RecruitingNCT07618195Updated Jun 1, 2026

Study of EPI-001 in Patients With Androgenetic Alopecia

A Phase 1/2 interventional study of EPI-001 and Placebo in Androgenetic Alopecia, sponsored by Epibiotech. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Epibiotech · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2026, registered May 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.

Planned enrollment
13th of 21
42 · median 80
Started
2026
with 1 other
Phase 1/2
3 of 22
2 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Epibiotech

Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 21st registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alopecia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.

In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration.

In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement, clinical photography, investigator assessment, expert panel assessment, and subject self-assessment during a follow-up period of up to 48 weeks.

Read the detailed description

Androgenetic alopecia (AGA) is one of the most common forms of hair loss in both men and women and is characterized by progressive hair follicle miniaturization associated with androgen sensitivity and genetic predisposition. Current treatment options for AGA are limited and may not provide sufficient therapeutic benefit for all patients.

EPI-001 is an autologous dermal papilla cell therapy intended for the treatment of androgenetic alopecia. This study is designed to evaluate the safety, tolerability, and efficacy of EPI-001 in subjects with androgenetic alopecia.

This study consists of two parts: a Phase I dose-escalation study and a Phase IIa dose-expansion study.

In the Phase I portion, subjects will receive a single administration of EPI-001 using a traditional 3+3 dose-escalation design to evaluate dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD), and establish the recommended Phase 2 dose (RP2D). Subjects will be followed for up to 24 weeks after administration.

In the Phase IIa portion, eligible subjects will be randomized in a 2:1 ratio to receive either EPI-001 at the RP2D or placebo. The study will evaluate efficacy through changes in total hair count and hair diameter, as well as investigator assessment, expert panel assessment based on clinical photographs, and subject self-assessment questionnaires. Subjects will undergo follow-up assessments for up to 48 weeks after administration.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • Hair Loss
  • Alopecia
  • Autologous Cell Therapy
  • Hair Regeneration
  • Dermal Papilla Cell
  • Cell therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 19 years or older
  2. Subjects diagnosed with androgenetic alopecia
  3. Subjects willing to maintain the same hairstyle, hair length, and hair color during the study period
  4. Subjects willing to refrain from prohibited hair-related products or procedures during the study period
  5. Subjects willing to undergo scalp tattooing and hair trimming for phototrichogram evaluation
  6. Subjects who voluntarily signed written

Exclusion criteria

Exclusion Criteria:

  1. Subjects who used prohibited medications or therapies affecting hair growth within the protocol-defined period
  2. Subjects with scalp diseases or hair disorders other than androgenetic alopecia
  3. Subjects with diseases affecting the scalp or hair
  4. Subjects with cardiovascular, renal, endocrine, infectious, or systemic diseases
  5. Subjects positive for , , , or syphilis screening tests
  6. Subjects with a history of hair transplantation, stem cell therapy, or gene therapy
  7. Subjects with related to the product or study procedures
  8. Pregnant or breastfeeding women
  9. Subjects who participated in another clinical study within the protocol-defined period
  10. Subjects judged inappropriate for study participation by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    EPI-001

    Biological: EPI-001

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalEPI-001

    EPI-001 is an autologous dermal papilla cell-based investigational product administered by subcutaneous injection to the scalp for the treatment of androgenetic alopecia.

  • OtherPlacebo

    Placebo control administered by subcutaneous injection to the scalp.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities

    Time frame: Up to 4 weeks after administration

Secondary outcomes

  1. Incidence of Adverse Events and Local Adverse Events

    Time frame: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration

  2. Number of Participants With Clinically Significant Abnormal Vital Signs

    Clinically significant abnormal vital signs include abnormalities in systolic blood pressure, diastolic blood pressure, pulse rate, and body temperature.

    Time frame: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration

  3. Number of Participants With Clinically Significant Laboratory Abnormalities

    Time frame: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration

  4. Investigator Assessment of Hair Growth Improvement Based on Clinical Photographs Using a 7-Point Scale

    Investigators assess hair growth improvement by comparing clinical photographs with baseline photographs using a 7-point scale ranging from -3 (greatly decreased) to +3 (greatly increased). Higher scores indicate greater improvement.

    Time frame: Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48

  5. Subject Self-Assessment of Hair Growth Improvement Using a 7-Point Questionnaire Scale

    Participants assess overall hair growth improvement using a questionnaire evaluating whether hair became fuller, reduction in hair shedding, increase in hair thickness, improvement in hair gloss and elasticity, improvement in overall scalp appearance, and increase in hair growth rate. Each item is scored on a 7-point scale ranging from -3 (greatly worsened) to +3 (greatly improved). Higher scores indicate greater perceived improvement.

    Time frame: Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48

  6. Change From Baseline in Total Hair Count Assessed by Phototrichogram

    Total hair count is assessed as the number of hairs identified within the target assessment area using phototrichogram imaging. Changes from baseline in total hair count within the target assessment area are evaluated.

    Time frame: Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48

  7. Change From Baseline in Mean Hair Diameter Assessed by Phototrichogram

    Mean hair diameter is assessed by measuring hair shaft thickness within the target assessment area using phototrichogram imaging. Changes from baseline in mean hair diameter are evaluated.

    Time frame: Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48

  8. Expert Panel Assessment of Hair Growth Improvement Based on Clinical Photographs Using a 7-Point Scale

    Expert panel members assess hair growth improvement by comparing clinical photographs with baseline photographs using a 7-point scale ranging from -3 (greatly decreased) to +3 (greatly increased). Higher scores indicate greater improvement.

    Time frame: Phase IIa: Weeks 12, 24, 36, and 48

07

Study locations

1 of 1 sites recruiting
  • Chung-Ang University Hospital
    Seoul, Seoul 06973, South Korea
    Recruiting
    • Chung-Ang University Hospital · Contact+82-1800-1114
    • Beom Joon Kim, MD, PhD. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) collected during the study will not be made publicly available due to the proprietary nature of the investigational product and ongoing clinical development.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 1, 2026
StartActual
Jan 12, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618195
Lead sponsor
Epibiotech
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jan 12, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Epibiotech Clinical Operations
Contact
info@epibiotech.com
+82-70-4209-0556

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion